ClinicalTrials.gg
RecruitingNCT05987397Updated Aug 14, 2023

Exploring the Preventive Effect of Mitochondrial Protective Agent Idebenone on Post-stroke Epilepsy

A Phase 4 interventional study of idebenone 30 mg for 14 days and idebenone 30 mg for 3 months in Post Stroke Epilepsy, sponsored by Xiangya Hospital of Central South University. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-08-14.

Sponsored by Xiangya Hospital of Central South University · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Jul 2023; still recruiting 3 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
2,700
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 101 studies in Epilepsy with a site in China — 35 open to participants now, 41 under way, 5 of them phase 3. Epilepsy · China.

Planned enrollment
2nd of 64
2,700 · median 141
Started
2023
with 7 others
Phase 4
5 of 101
3 open now
Primary completion
2025-12
later than 8 of 40 live
Registered
70th of 101
by date

Among the 101 studies in Epilepsy with a site in China, this one is the 2nd largest by planned enrollment of the 64 interventional ones that give a count, is one of 8 that started in 2023, is one of 5 in phase 4, reaches primary completion later than 8 of the 40 other live ones, and was the 70th registered.

Epilepsy

1,850 studies on the registry are indexed under Epilepsy; 418 are open to participants now.

Browse Epilepsy studies →

Open to participants now

35 of the 101 studies in Epilepsy with a site in China are open now. Recruiting first, the newest first:

29 more — sign in →

All 35 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 284 Epilepsy studies recruiting now, 113 (40%) set no upper age limit and 148 (52%) stop at 75 or younger; 138 take children under 18; 54 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 101 studies in Epilepsy with a site in China, or all of them as a file.
02

Study summary

According to the random number table, all patients were divided into short-term treatment group, long-term treatment group and non-intervention stroke control group according to the proportion of (1:1:1) epilepsy disease modifier idebenone. Patients in the short-term treatment group will take idebenone for a total course of 14 days (acute period) after stroke, and patients in the long-term treatment group will take idebenone for a total course of 3 months after stroke.

03

Conditions studied

  • Post Stroke Epilepsy

Keywords

  • post-stroke epilepsy
  • idebenone
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients admitted to hospital within 24 hours of stroke symptoms and diagnosed with stroke (including cerebral infarction, cerebral hemorrhage, subarachnoid hemorrhage, intracranial venous sinus thrombosis, etc.) after relevant examinations;
  • Able to cooperate with the inspection;
  • Sign the form.

Exclusion criteria

Exclusion Criteria:

  • History of epilepsy before stroke;
  • A history of serious comorbidities that may lead to seizures (including malignant tumors, specific diseases, severe electrolyte abnormalities, end-stage renal disease, and severe head trauma);
  • Secondary stroke caused by head trauma or surgery;
  • Other patients that the researchers think need to be excluded.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2,700 participants (estimated)

Study arms

  • Experimental
    Group A: Idebenone short-term treatment group

    The patient received oral idebenone 30 mg three times a day after stroke for a total course of 14 days (acute phase).

    Drug: idebenone 30 mg for 14 days

  • Experimental
    Group B: Idebenone long-term treatment group

    The patient will be treated with oral idebenone 30 mg three times a day after stroke for a total course of 3 months.

    Drug: idebenone 30 mg for 3 months

Interventions

  • DrugIdebenoneStudies of IdebenoneIdebenone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The patient received oral idebenone 30 mg three times a day after stroke for a total course of 14 days (acute phase).

  • DrugIdebenoneStudies of IdebenoneIdebenone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The patient will be treated with oral idebenone 30 mg three times a day after stroke for a total course of 3 months.

06

What researchers measure

Primary outcomes

  1. The proportion of patients with epilepsy after stroke

    Count the number of people with post-stroke epilepsy

    Time frame: At the time of enrollment

  2. The proportion of patients with epilepsy after stroke

    Count the number of people with post-stroke epilepsy

    Time frame: 24 weeks after enrollment

  3. The proportion of patients with epilepsy after stroke

    Count the number of people with post-stroke epilepsy

    Time frame: 48 weeks after enrollment

Secondary outcomes

  1. National Institutes of Health Stroke Scale (NIHSS)

    The minimum value is 0, the maximum value is 24, the higher score indicates the more severe neurological impairment in stroke patients

    Time frame: At the time of enrollment

  2. National Institutes of Health Stroke Scale (NIHSS)

    The minimum value is 0, the maximum value is 24, the higher score indicates the more severe neurological impairment in stroke patients

    Time frame: 24 weeks after enrollment

  3. National Institutes of Health Stroke Scale (NIHSS)

    The minimum value is 0, the maximum value is 24, the higher score indicates the more severe neurological impairment in stroke patients

    Time frame: 48 weeks after enrollment

  4. Hamilton Anxiety Scale (HAMA)

    The minimum value is 0, the maximum value is 56, the higher score indicates a great likelihood of anxiety

    Time frame: At the time of enrollment

  5. Hamilton Anxiety Scale (HAMA)

    The minimum value is 0, the maximum value is 56, the higher score indicates a great likelihood of anxiety

    Time frame: 24 weeks after enrollment

  6. Hamilton Anxiety Scale (HAMA)

    The minimum value is 0, the maximum value is 56, the higher score indicates a great likelihood of anxiety

    Time frame: 48 weeks after enrollment

  7. Hamilton Depression Scale (HAMD)

    The minimum value is 0, the maximum value is 77, the higher score indicates a great likelihood of depression

    Time frame: At the time of enrollment

  8. Hamilton Depression Scale (HAMD)

    The minimum value is 0, the maximum value is 77, the higher score indicates a great likelihood of depression

    Time frame: 24 weeks after enrollment

  9. Hamilton Depression Scale (HAMD)

    The minimum value is 0, the maximum value is 77, the higher score indicates a great likelihood of depression

    Time frame: 48 weeks after enrollment

  10. Pittsburgh sleep quality index (PSQI)

    The minimum value is 0, the maximum value is 21, the higher score indicates poorer sleep quality

    Time frame: At the time of enrollment

  11. Pittsburgh sleep quality index (PSQI)

    The minimum value is 0, the maximum value is 21, the higher score indicates poorer sleep quality

    Time frame: 24 weeks after enrollment

  12. Pittsburgh sleep quality index (PSQI)

    The minimum value is 0, the maximum value is 21, the higher score indicates poorer sleep quality

    Time frame: 48 weeks after enrollment

  13. Stroke specific quality of life scale (SS-QOL)

    The minimum value is 38, the maximum value is 190, the higher score indicates better quality of life

    Time frame: At the time of enrollment

  14. Stroke specific quality of life scale (SS-QOL)

    The minimum value is 38, the maximum value is 190, the higher score indicates better quality of life

    Time frame: 24 weeks after enrollment

  15. Stroke specific quality of life scale (SS-QOL)

    The minimum value is 38, the maximum value is 190, the higher score indicates better quality of life

    Time frame: 48 weeks after enrollment

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2023 (actual). Primary completion is estimated for Dec 2025, 29 months after the start.

Of 33 non-industry phase 4 interventional studies under Epilepsy, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 37. This study's planned 29 months is above that.

Counting every sponsor, half of 43 studies reached it within 25 months; a quarter within 12 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 19, 2023
First posted
Aug 14, 2023
StartActual
Jul 5, 2023
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2025
Last update
Aug 14, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05987397
Responsible party
Li Feng, MD, PhD (Associate Professor Vice Director of Neurology Teaching and Research Office, Xiangya Hospital of Central South University) — Principal investigator
First posted
Aug 14, 2023
Start date
Jul 5, 2023
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Aug 14, 2023

Study contacts

Li Feng, PhD
Contact
fenglihx@163.com
86-13873123853

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Idebenone

Start the discussion